# Acceptability of a clofazimine tablet in children with rifampicin-resistant TB in three high-burden countries

**Authors:** L. Viljoen, H.R. Draper, N.T. Castillo-Carandang, N. Suryavanshi, A. Marthinus, A.M.A. Cheong, J.D.D. Ocampo, G. Dhumal, S. Bagchi, D.T. Wademan, A. Kinikar, M. Paradkar, M.V.G. Frias, D.J.O. Casalme, A.C. Hesseling, A.J. Garcia-Prats, M. Palmer, G. Hoddinott

PMC · DOI: 10.5588/ijtldopen.25.0309 · IJTLD OPEN · 2025-08-13

## TL;DR

A new 50mg clofazimine tablet is easier for children and caregivers to use compared to the old gel capsule for treating drug-resistant TB.

## Contribution

The study introduces and evaluates a novel 50mg clofazimine tablet formulation for improved child and caregiver acceptability.

## Key findings

- The 50mg tablet had better acceptability scores for taste, smell, and ease of swallowing compared to the gel capsule.
- Participants found the tablet easier to administer without lingering smell or taste.
- Limited concerns about staining were reported with the new tablet formulation.

## Abstract

Rifampicin-resistant TB (RR-TB) in children is frequently treated with clofazimine (CFZ), widely available as a 100mg gel capsule. This formulation is challenging to administer and is poorly acceptable to children and caregivers. Poor acceptability may negatively impact adherence and treatment outcomes. We describe the acceptability of a novel 50mg CFZ tablet formulation among children in South Africa, India, and the Philippines.

Mixed methods assessments were completed in a moxifloxacin and CFZ safety and pharmacokinetics trial in children with RR-TB. Quantitative data were collected from 36 participants at 4 timepoints. A sub-sample of 26 child/caregiver dyads participated in ∼4 qualitative interviews. Descriptive statistics and thematic analysis were employed.

The median age of n=36 participants (South Africa n=20; India n=6; the Philippines n=10) was 4.9 years. The majority (29/36) received a CFZ gel capsule prior to switching to the tablet formulation. The 50mg tablet had better acceptability scores for taste (p=0.035), smell (p=0.035), and ease of swallowing (p=0.02) compared to gel capsules. Participants described the tablet formulation as easier to administer/take without a lingering smell or taste. Limited concerns were noted on staining.

The novel 50mg CFZ tablet has better acceptability and should be prioritised for children wherever possible.

## Linked entities

- **Chemicals:** clofazimine (PubChem CID 2794), moxifloxacin (PubChem CID 152946), rifampicin (PubChem CID 135398735)
- **Diseases:** TB (MONDO:0018076), RR-TB (MONDO:0100479)

## Full-text entities

- **Diseases:** RR-TB (MESH:D014390), Hyperpigmentation (MESH:D017495), insomnia (MESH:D007319), cardiac rhythm abnormalities (MESH:D018376), dizziness (MESH:D004244), COVID-19 (MESH:D000086382), nausea (MESH:D009325), gastrointestinal irritation (MESH:D005767), MDR-TB (MESH:D018088), diarrhoea (MESH:D003967), abdominal pain (MESH:D015746), QT prolongation (MESH:D008133), headaches (MESH:D006261), vomit (MESH:D014839)
- **Chemicals:** Chocolate drink (-), Aspirin (MESH:D001241), CFZ (MESH:D002991), isoniazid (MESH:D007538), Rifampicin (MESH:D012293), moxifloxacin (MESH:D000077266), sugar (MESH:D000073893), water (MESH:D014867)
- **Species:** Mycobacterium tuberculosis (species) [taxon 1773], Homo sapiens (human, species) [taxon 9606], Human immunodeficiency virus 1 (no rank) [taxon 11676]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12352948/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12352948/full.md

## References

28 references — full list in the complete paper: https://tomesphere.com/paper/PMC12352948/full.md

---
Source: https://tomesphere.com/paper/PMC12352948